查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1803145

全球迷幻微剂量市场：2032 年预测 - 按成分、给药途径、分销管道、应用和地区进行分析

Psychedelic Microdosing Market Forecasts to 2032 - Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球迷幻微剂量市场预计在 2025 年达到 21 亿美元，到 2032 年将达到 58 亿美元，预测期内的复合年增长率为 15%。

迷幻微剂量是指摄取极少量、低于感知剂量的迷幻物质，例如LSD或裸盖菇素，通常为娱乐剂量的十分之一到二十分之一。与产生幻觉或强烈感知改变的完全迷幻体验不同，微剂量旨在产生微妙的认知、情绪和生理益处，而不会显着损害日常功能。支持者指出，微剂量可以增强创造力、专注力、情绪稳定性和情绪健康，同时还可以减轻焦虑和忧郁症状。虽然其潜在的心理健康和生产力益处使其越来越受欢迎，但关于其安全性、有效性和长期影响的科学研究仍然有限且仍在进行中。

对新型心理健康治疗的需求不断增长

忧郁症、焦虑症和创伤后压力症候群（PTSD）的盛行率不断上升，暴露了传统治疗方法的不足。迷幻药微剂量因其能够改善情绪、增强注意力、促进心理健康，同时最大程度地减少副作用而备受关注。公众意识的不断提升，加上积极的临床观察，正在提高患者和医疗保健相关人员对迷幻药的接受度。这种势头正在推动对安全、受监管的迷幻疗法开发的投资，从而使迷幻药市场迅速扩张，应用范围也更加广泛。

关于微剂量的高品质临床证据有限

由于缺乏强有力的临床试验，监管机构对核准或支持微剂量疗法持谨慎态度。缺乏检验也降低了投资者信心，并限制了研究和商业化的资金投入。有限的科学证据进一步阻碍了医疗保健专业人员推荐微剂量疗法。因此，消费者的接受速度缓慢，且主要受传闻经验而非临床检验的影响。最终，缺乏可靠的证据阻碍了市场扩张，并延迟了更广泛的接受度。

新的产品形式和分销管道

胶囊、软糖、鼻喷雾和舌下含片等创新产品形式，实现了便捷精准的给药。这些形式使微剂量给药更加便捷，减少污名化，进而吸引更广泛的消费者群体。线上平台、远端医疗服务和健康诊所透过提供谨慎安全的途径，进一步加强了分销。零售合作伙伴关係和数位市场也有助于提高认知度和消费者信任度。这些进步将共同推动微剂量给药的广泛应用和市场成长。

法规和法律障碍

许多国家严格的药品分类法限制了迷幻药的研究、临床试验和治疗应用。冗长的核准流程和复杂的合规要求阻碍了新参与企业的创新和市场准入。缺乏统一的全球法规进一步限制了跨国合作与扩张。对法律影响的担忧阻碍了该领域的投资和业务发展。总体而言，这些障碍减缓了该领域的应用，并限制了市场的成长潜力。

COVID-19的影响

新冠疫情对迷幻微剂量市场产生了多重影响。一方面，它限制了临床试验和研究，延缓了产品开发和监管进程。供应链中断也影响了原料的取得和迷幻产品的供应。然而，疫情也加剧了焦虑、忧郁症和压力等心理健康挑战，导致人们对微剂量等替代疗法的兴趣日益浓厚。在此期间，远端医疗和数位心理健康平台的普及进一步提升了人们对迷幻微剂量的认知和讨论。

预计在预测期内，裸盖菇素类药物的市占率将达到最大

由于裸盖菇素在心理健康研究和治疗领域的接受度不断提高，预计将在预测期内占据最大的市场占有率。越来越多的临床研究强调了裸盖菇素在治疗忧郁症、焦虑症和创伤后压力症候群方面的有效性，这推动了对可控微剂量的需求。社会意识的增强和对天然迷幻药的污名化减少进一步推动了其应用。此外，一些地区的监管机构正在放宽监管，为裸盖菇素的商业性应用开闢了机会。总体而言，裸盖菇素强大的治疗潜力和不断变化的认知是市场成长的关键驱动力。

预计认知增强领域在预测期内将以最高的复合年增长率成长。

预计认知增强领域将在预测期内实现最高成长率，吸引那些寻求提升专注力、创造力和生产力的人。专业人士、学生和企业家日益增长的兴趣正在推动需求成长，因为微剂量如今被视为优化心理表现的工具。科学研究和传闻证据强调了其在提高问题解决能力和记忆力等方面的益处，这进一步增强了市场接受度。精神活性药物与健康趋势的日益融合也使微剂量成为主流。整体而言，认知增强正成为关键驱动因素，将微剂量定位为一种提升表现的生活方式选择。

比最大的地区

在预测期内，北美预计将占据最大的市场占有率，这得益于人们对心理健康的认识不断提高以及社会对替代疗法的态度转变。对研究、临床试验和新兴企业系统的持续投资正在加速产品创新和发展。公众对健康和个人生产力的关注进一步刺激了需求。美国某些州和加拿大地区推出了支持性倡议，推动法规的逐步转变，创造出更开放的环境。然而，儘管消费者的兴趣和机构支持继续推动市场成长，但法律的不确定性和污名化仍然是挑战。

复合年增长率最高的地区：

预计欧洲将在预测期内实现最高的复合年增长率，这得益于健康社区、心理健康专业人士和研究机构的浓厚兴趣。人们对焦虑、忧郁症和认知能力替代疗法的认识日益提高，这正在塑造需求。各国的法规各不相同，既创造了机会，也带来了障碍。学术研究和临床试验增强了可信度，而健康旅游和生活方式趋势也激发了人们的好奇心。文化对整体健康实践的接受度也在推动其应用，儘管一些国家的限制性法律体制阻碍了其更广泛的商业化。

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 应用分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

5. 全球迷幻微剂量市场（依成分）

  • 裸盖菇素
  • LSD
  • 氯胺酮
  • MDMA
  • 其他化合物

6. 全球迷幻微剂量市场（依给药途径）

  • 口服
  • 舌下
  • 鼻腔
  • 经皮
  • 其他给药途径

7. 全球迷幻微剂量市场（依通路）

  • 处方笺
  • 直接面向消费者
  • 研究用品

8. 全球迷幻微剂量市场（依应用）

  • 心理健康
  • 认知功能增强
  • 健康与生活方式
  • 成瘾治疗
  • 家庭使用
  • 其他用途

9. 全球迷幻微剂量市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • COMPASS Pathways
  • MindMed Inc.
  • Cybin Inc.
  • Atai Life Sciences
  • Beckley Psytech
  • Seelos Therapeutics
  • Delix Therapeutics
  • Eleusis
  • GH Research PLC
  • Awakn Life Sciences
  • Numinus Wellness
  • Mydecine Innovations Group
  • Entheon Biomedical
  • Wesana Health
  • Tryp Therapeutics
  • Enveric Biosciences
  • Clairvoyant Therapeutics
Product Code: SMRC30670

According to Stratistics MRC, the Global Psychedelic Microdosing Market is accounted for $2.1 billion in 2025 and is expected to reach $5.8 billion by 2032 growing at a CAGR of 15% during the forecast period. Psychedelic microdosing refers to the practice of consuming very small, sub-perceptual doses of psychedelic substances such as LSD or psilocybin, typically around one-tenth to one-twentieth of a recreational dose. Unlike full psychedelic experiences that cause hallucinations and intense alterations in perception, microdosing aims to deliver subtle cognitive, emotional, and physiological benefits without significantly impairing daily functioning. Advocates suggest that microdosing may enhance creativity, focus, mood stability, and emotional well-being, while reducing anxiety or depression symptoms. Although gaining popularity for potential mental health and productivity benefits, scientific research on its safety, efficacy, and long-term effects remains limited and ongoing.

Market Dynamics:

Driver:

Rising demand for new mental-health treatments

The rising prevalence of depression, anxiety, and PTSD has exposed the shortcomings of conventional treatments. Microdosing psychedelics is gaining attention for its ability to elevate mood, sharpen focus, and promote mental well-being with reduced adverse effects. Increasing public awareness combined with positive clinical findings is fostering greater acceptance among both patients and medical professionals. This momentum is driving investments in the development of safe, regulated psychedelic therapies. Consequently, the market is experiencing rapid expansion and wider utilization.

Restraint:

Limited high-quality clinical evidence for microdosing

Lack of robust clinical trials makes regulatory authorities cautious about granting approval or support for microdosing. Insufficient validation also diminishes investor trust and limits financial backing for research and commercialization. Limited scientific proof further discourages healthcare professionals from recommending its use. Consumer adoption therefore remains slow and is primarily shaped by anecdotal experiences rather than clinical validation. In turn, the shortage of reliable evidence hinders market expansion and delays wider acceptance.

Opportunity:

New product formats & distribution channels

Innovative product forms such as capsules, gummies, nasal sprays, and sublingual strips offer convenient and precise dosing. These formats appeal to a wider consumer base by making microdosing more approachable and less stigmatized. Online platforms, telehealth services, and wellness clinics further enhance distribution by providing discreet and safe access. Retail partnerships and digital marketplaces also help increase visibility and consumer trust. Together, these advancements drive broader adoption and market growth.

Threat:

Regulatory & legal barriers

Strict drug classification laws in many countries restrict research, clinical trials, and therapeutic applications of psychedelics. Lengthy approval processes and complex compliance requirements slow down innovation and market entry for new players. The lack of harmonized global regulations further limits cross-border collaboration and expansion. Fear of legal repercussions discourages investment and business development in the sector. Overall, these barriers delay adoption and restrict the market's growth potential.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the psychedelic microdosing market. On one hand, restrictions on clinical trials and research slowed product development and regulatory progress. Supply chain disruptions also affected access to raw materials and delivery of psychedelic-based products. However, the pandemic increased mental health challenges such as anxiety, depression, and stress, leading to growing interest in alternative therapies like microdosing. The shift toward telemedicine and digital mental health platforms further supported awareness and discussions around psychedelic microdosing during this period.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is expected to account for the largest market share during the forecast period, due to its growing acceptance in mental health research and therapy. Increasing clinical studies highlight psilocybin's effectiveness in treating depression, anxiety, and PTSD, driving demand for controlled microdosing. Rising public awareness and reduced stigma around natural psychedelics further encourage adoption. Additionally, regulatory bodies in some regions are easing restrictions, opening opportunities for commercial applications. Overall, psilocybin's strong therapeutic potential and shifting perceptions make it a key growth driver for the market.

The cognitive enhancement segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cognitive enhancement segment is predicted to witness the highest growth rate by attracting individuals seeking improved focus, creativity, and productivity. Rising interest from professionals, students, and entrepreneurs fuels demand as microdosing is increasingly viewed as a tool for mental performance optimization. Scientific studies and anecdotal evidence highlighting benefits like better problem-solving and memory retention further strengthen market adoption. The growing integration of nootropics and wellness trends also aligns with the microdosing movement, making it more mainstream. Overall, cognitive enhancement acts as a key driver by positioning microdosing as a performance-boosting lifestyle choice.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising mental health awareness and shifting societal attitudes toward alternative therapies. Increasing investment in research, clinical trials, and startup ecosystems is accelerating product innovation and development. Public discourse around wellness and personal productivity further strengthens demand. Supportive initiatives in certain U.S. states and Canadian regions foster progressive regulatory shifts, creating a more open environment. However, legal uncertainties and stigma remain challenges, though consumer interest and institutional backing continue to push market growth.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to strong interest from wellness communities, mental health practitioners, and research organizations. Growing awareness of alternative treatments for anxiety, depression, and cognitive performance is shaping demand. Regulations are mixed across countries, creating both opportunities and barriers. Academic studies and clinical trials drive credibility, while wellness tourism and lifestyle trends also fuel curiosity. The cultural acceptance of holistic health practices supports adoption, though stricter legal frameworks in several nations slow down wider commercialization.

Key players in the market

Some of the key players profiled in the Psychedelic Microdosing Market include COMPASS Pathways, MindMed Inc., Cybin Inc., Atai Life Sciences, Beckley Psytech, Seelos Therapeutics, Delix Therapeutics, Eleusis, GH Research PLC, Awakn Life Sciences, Numinus Wellness, Mydecine Innovations Group, Entheon Biomedical, Wesana Health, Tryp Therapeutics, Enveric Biosciences, and Clairvoyant Therapeutics.

Key Developments:

In April 2025, Cybin secured Strategic Partnership Agreements with 18 clinical sites for its Phase 3 CYB003 program. These collaborations aim to streamline operations, boost patient recruitment, and standardize protocols across the PARADIGM trial's multinational infrastructure.

In February 2024, MindMed partnered with Sphere Health to advance digital biomarkers and remote monitoring for psychedelic therapies, including microdosing. The collaboration integrates wearable tech with clinical protocols to enhance patient tracking, dose-response analysis, and personalized treatment optimization.

In January 2024, COMPASS entered a three-year research collaboration with Greenbrook TMS to pilot COMP360 psilocybin therapy across U.S. clinics. The initiative targets treatment-resistant depression, optimizing therapist workflows, patient experience, and digital integration for scalable delivery.

Compounds Covered:

  • Psilocybin
  • LSD
  • Ketamine
  • MDMA
  • Other Compounds

Route of Administrations Covered:

  • Oral
  • Sublingual
  • Nasal
  • Transdermal
  • Other Route of Administrations

Distribution Channels Covered:

  • Prescription
  • Direct-to-consumer
  • Research supply

Applications Covered:

  • Mental health
  • Cognitive enhancement
  • Wellness and lifestyle
  • Addiction treatment
  • Home use
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Psychedelic Microdosing Market, By Compound

  • 5.1 Introduction
  • 5.2 Psilocybin
  • 5.3 LSD
  • 5.4 Ketamine
  • 5.5 MDMA
  • 5.6 Other Compounds

6 Global Psychedelic Microdosing Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Sublingual
  • 6.4 Nasal
  • 6.5 Transdermal
  • 6.6 Other Route of Administrations

7 Global Psychedelic Microdosing Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Prescription
  • 7.3 Direct-to-consumer
  • 7.4 Research supply

8 Global Psychedelic Microdosing Market, By Application

  • 8.1 Introduction
  • 8.2 Mental health
  • 8.3 Cognitive enhancement
  • 8.4 Wellness and lifestyle
  • 8.5 Addiction treatment
  • 8.6 Home use
  • 8.7 Other Applications

9 Global Psychedelic Microdosing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 COMPASS Pathways
  • 11.2 MindMed Inc.
  • 11.3 Cybin Inc.
  • 11.4 Atai Life Sciences
  • 11.5 Beckley Psytech
  • 11.6 Seelos Therapeutics
  • 11.7 Delix Therapeutics
  • 11.8 Eleusis
  • 11.9 GH Research PLC
  • 11.10 Awakn Life Sciences
  • 11.11 Numinus Wellness
  • 11.12 Mydecine Innovations Group
  • 11.13 Entheon Biomedical
  • 11.14 Wesana Health
  • 11.15 Tryp Therapeutics
  • 11.16 Enveric Biosciences
  • 11.17 Clairvoyant Therapeutics

List of Tables

  • Table 1 Global Psychedelic Microdosing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 3 Global Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 4 Global Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 5 Global Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 6 Global Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 7 Global Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 8 Global Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 9 Global Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 10 Global Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 11 Global Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 12 Global Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 13 Global Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 14 Global Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 15 Global Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 16 Global Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 17 Global Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 18 Global Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 20 Global Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 21 Global Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 22 Global Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 23 Global Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 24 Global Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 25 North America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 26 North America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 27 North America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 28 North America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 29 North America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 30 North America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 31 North America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 32 North America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 33 North America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 34 North America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 35 North America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 36 North America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 37 North America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 38 North America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 39 North America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 40 North America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 41 North America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 42 North America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 43 North America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 44 North America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 45 North America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 46 North America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 47 North America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 48 North America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 49 Europe Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 50 Europe Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 51 Europe Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 52 Europe Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 53 Europe Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 54 Europe Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 55 Europe Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 56 Europe Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 57 Europe Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 58 Europe Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 59 Europe Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 60 Europe Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 61 Europe Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 62 Europe Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 63 Europe Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 64 Europe Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 65 Europe Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 66 Europe Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 67 Europe Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 68 Europe Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 69 Europe Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 70 Europe Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 71 Europe Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 72 Europe Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 73 Asia Pacific Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 74 Asia Pacific Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 75 Asia Pacific Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 76 Asia Pacific Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 77 Asia Pacific Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 78 Asia Pacific Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 79 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 80 Asia Pacific Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 81 Asia Pacific Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 82 Asia Pacific Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 83 Asia Pacific Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 84 Asia Pacific Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 85 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 86 Asia Pacific Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 87 Asia Pacific Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 88 Asia Pacific Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 89 Asia Pacific Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 90 Asia Pacific Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 91 Asia Pacific Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 92 Asia Pacific Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 93 Asia Pacific Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 94 Asia Pacific Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 95 Asia Pacific Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 96 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 97 South America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 98 South America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 99 South America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 100 South America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 101 South America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 102 South America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 103 South America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 104 South America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 105 South America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 106 South America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 107 South America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 108 South America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 109 South America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 110 South America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 111 South America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 112 South America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 113 South America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 114 South America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 115 South America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 116 South America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 117 South America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 118 South America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 119 South America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 120 South America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 121 Middle East & Africa Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
  • Table 122 Middle East & Africa Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
  • Table 123 Middle East & Africa Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
  • Table 124 Middle East & Africa Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
  • Table 125 Middle East & Africa Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
  • Table 126 Middle East & Africa Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
  • Table 127 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
  • Table 128 Middle East & Africa Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 129 Middle East & Africa Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
  • Table 130 Middle East & Africa Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
  • Table 131 Middle East & Africa Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 132 Middle East & Africa Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 133 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 134 Middle East & Africa Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 135 Middle East & Africa Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
  • Table 136 Middle East & Africa Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
  • Table 137 Middle East & Africa Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
  • Table 138 Middle East & Africa Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
  • Table 139 Middle East & Africa Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
  • Table 140 Middle East & Africa Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
  • Table 141 Middle East & Africa Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
  • Table 142 Middle East & Africa Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
  • Table 143 Middle East & Africa Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
  • Table 144 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)